An overview of targeted alpha therapy with 225 Actinium and 213 Bismuth
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
Current radiopharmaceuticals
Year: 2018, Volume: 11, Issue: 3, Pages: 200-208 |
| ISSN: | 1874-4729 |
| Online Access: | Verlag, Pay-per-use, Volltext: http://www.eurekaselect.com/161764/article
|
| Author Notes: | Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 166306797X | ||
| 003 | DE-627 | ||
| 005 | 20220816132753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190410s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1874471011666180502104524 |2 doi | |
| 035 | |a (DE-627)166306797X | ||
| 035 | |a (DE-599)KXP166306797X | ||
| 035 | |a (OCoLC)1341208988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Morgenstern, Alfred |e VerfasserIn |0 (DE-588)1183152809 |0 (DE-627)1663069069 |4 aut | |
| 245 | 1 | 3 | |a An overview of targeted alpha therapy with 225 Actinium and 213 Bismuth |c Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer |
| 264 | 1 | |c 2018 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.04.2019 | ||
| 500 | |a Im Titel sind die Ziffern "225" und "213" hoch gestellt | ||
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current radiopharmaceuticals |d Sharjah : Bentham Science Publ., 2008 |g 11(2018), 3, Seite 200-208 |h Online-Ressource |w (DE-627)570505488 |w (DE-600)2433114-4 |w (DE-576)299311066 |x 1874-4729 |7 nnas |a An overview of targeted alpha therapy with 225 Actinium and 213 Bismuth |
| 773 | 1 | 8 | |g volume:11 |g year:2018 |g number:3 |g pages:200-208 |g extent:9 |a An overview of targeted alpha therapy with 225 Actinium and 213 Bismuth |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/161764/article |x Verlag |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190410 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 999 | |a KXP-PPN166306797X |e 3421266069 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Alfred Morgenstern, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer"]},"recId":"166306797X","id":{"eki":["166306797X"],"doi":["10.2174/1874471011666180502104524"]},"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"language":["eng"],"physDesc":[{"extent":"9 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Morgenstern, Alfred","family":"Morgenstern","role":"aut","given":"Alfred"},{"role":"aut","given":"Clemens","family":"Kratochwil","display":"Kratochwil, Clemens"}],"title":[{"title":"An overview of targeted alpha therapy with 225 Actinium and 213 Bismuth","title_sort":"overview of targeted alpha therapy with 225 Actinium and 213 Bismuth"}],"relHost":[{"title":[{"title":"Current radiopharmaceuticals","title_sort":"Current radiopharmaceuticals"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2008 -"],"language":["eng"],"note":["Gesehen am 03.07.2023"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"11","pages":"200-208","extent":"9","text":"11(2018), 3, Seite 200-208","issue":"3","year":"2018"},"origin":[{"dateIssuedDisp":"2008-","publisher":"Bentham Science Publ.","dateIssuedKey":"2008","publisherPlace":"Sharjah"}],"id":{"zdb":["2433114-4"],"issn":["1874-4729"],"eki":["570505488"]},"disp":"An overview of targeted alpha therapy with 225 Actinium and 213 BismuthCurrent radiopharmaceuticals","recId":"570505488"}],"note":["Gesehen am 10.04.2019","Im Titel sind die Ziffern \"225\" und \"213\" hoch gestellt"]} | ||
| SRT | |a MORGENSTEROVERVIEWOF2018 | ||